Genetic Technologies Limited (GENE) Directors and Executive Officers

Officers & Directors

Peter Rubinstein
Chairman
Melbourne

Peter Rubinstein
Director
Melbourne

Simon Morriss
Name

GRANT THORNTON AUDIT PTY LTD
.,

News about Genetic Technologies Limited Key Personnel

Genetic Technologies Limited: Solid Gain in Shares Amidst Expansion into New Global Markets

Genetic Technologies Limited (NASDAQ: GENE) is making significant strides in the field of personalized predictive genomics, transforming the healthcare industry with its groundbreaking approach to early disease detection and personalized wellness. With the release of its business update for the quarter ending 31 December 2023, the company has reported a stellar 9.38% gain in shares over the past five trading days. This positive development comes as Genetic Technologies Limited expands its reach into new global markets, aiming to reshape healthcare practices on a global scale.
Expanding into New Global Markets:
Genetic Technologies Limited s latest business update outlines the successful exp...

Genetic Technologies Achieves Compliance with Nasdaq Minimum Bid Price Requirement, Rebounding from Previous Challenges

Melbourne, Australia - In an exciting development, Genetic Technologies Limited (NASDAQ: GENE) announces that it has regained compliance with the minimum bid price requirement prescribed by the Nasdaq Stock Market, LLC (Nasdaq). The leading global genomics-based test provider, specializing in health, wellness, and serious diseases, received formal notice from Nasdaq confirming its successful compliance with the Nasdaq Listing Rule 5550(a)(2).
Earlier, on July 17, 2023, Genetic Technologies had received written notice from Nasdaq indicating its failure to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market. However, the company has effectively a...